



1812  
VLM

1812

#4  
MB  
11/28/95

PATENT DOCKET P0897P2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of ) Group Art Unit: 1812  
GOEDDEL and ROTHE )  
Serial No. 08/446,915 )  
Filed: 22 MAY 1995 )  
For: TUMOR NECROSIS FACTOR RECEPTOR- )  
ASSOCIATED FACTORS )  
)

**CERTIFICATE OF MAILING**  
I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first-class mail in an envelope  
addressed to: Commissioner of Patents and Trademarks,  
Washington, D.C. 20231 on  
**30 August 1995**  
(Date of Deposit)  
**Aida A. Miclat**  
Name of Depositing Party  
**Aida A. Miclat**  
Signature of Depositing Party  
**30 August 1995**  
Date of Signature

Draper  
10-18  
030

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Honorable Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. §§1.56 and 1.97, applicants bring to the attention of the Patent Office an oral presentation by Mike Rothe, an inventor of the above-identified patent application, delivered on May 31, 1994 at the 5th International Congress on TNF and Related Cytokines, Monterey, California. The presentation focused on the TRAF1 and TRAF2 polypeptides, essentially as disclosed in the later-published paper Rothe *et al.*, *Cell* 78, 681-692 (1994).

While the information disclosed herein may be "material" pursuant to 37 C.F.R. §1.56, it is not intended to constitute an admission that it is "prior art" for this invention. Indeed, all claims in the present application are believed to be entitled to the May 27, 1994 priority date of parent application Serial No. 08/250,858, which precedes the date of the above-identified oral presentation. In accordance with 37 C.F.R. §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. It is

submitted that this Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the disclosed information.

Respectfully submitted,  
GENENTECH, INC.

Date: 30 August 1995

By: Ginger R. Dreger  
Ginger R. Dreger  
Reg. No. 33,055

460 Pt. San Bruno Blvd.  
So. San Francisco, CA 94080-4990  
Phone: (415) 225-3216  
Fax: (415) 952-9881